{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T22:53:06Z","timestamp":1772059986396,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12913-018-3272-x","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T08:12:43Z","timestamp":1530605563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Physicians\u2019 preferences for bone metastases treatments in France, Germany and the United Kingdom"],"prefix":"10.1186","volume":"18","author":[{"given":"Yi","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Hechmati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ateesha F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"3272_CR1","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s\u20139s.","journal-title":"Clin Cancer Res"},{"key":"3272_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Foss\u00e5 SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franz\u00e9n L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland \u00d8S, Sartor O, ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"3272_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00520-006-0166-y","volume":"15","author":"DA Loblaw","year":"2007","unstructured":"Loblaw DA, Wu JS, Kirkbride P, Panzarella T, Smith K, Aslanidis J, Warde P. Pain flare in patients with bone metastases after palliative radiotherapy \u2013 a nested randomized control trial. Support Care Cancer. 2007;15:451\u20135.","journal-title":"Support Care Cancer"},{"key":"3272_CR4","doi-asserted-by":"crossref","unstructured":"Chow E, Hoskin P, van der Linden Y, Bottomley A, Velikova G. Quality of life and symptom end points in palliative bone metastases trials. Clin Oncol (R Coll Radiol) 2006;18:67\u201369.","DOI":"10.1016\/j.clon.2005.06.016"},{"key":"3272_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lungcan.2009.08.020","volume":"67","author":"C Langer","year":"2010","unstructured":"Langer C, Hirsh V. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer. 2010;67:4\u201311.","journal-title":"Lung Cancer"},{"key":"3272_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","volume":"36","author":"TA Plunkett","year":"2000","unstructured":"Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. Implications for management Eur J Cancer. 2000;36:476\u201382.","journal-title":"Implications for management Eur J Cancer"},{"key":"3272_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M. Zoledronic Acid Prostate Cancer Study Group: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879\u201382.","journal-title":"J Natl Cancer Inst"},{"key":"3272_CR8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00520-013-1755-1","volume":"21","author":"R von Moos","year":"2013","unstructured":"von Moos R, Sternberg C, Body JJ, Bokemeyer C. Reducing the burden of bone metastases: current concepts and treatment options. Support Care Cancer. 2013;21:1773\u201383.","journal-title":"Support Care Cancer"},{"key":"3272_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00402-001-0359-2","volume":"122","author":"A Katzer","year":"2002","unstructured":"Katzer A, Meenen NM, Grabbe F, Rueger JM. Surgery of skeletal metastases. Arch Orthop Trauma Surg. 2002;122:251\u20138.","journal-title":"Arch Orthop Trauma Surg"},{"key":"3272_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0959-8049(97)10128-9","volume":"34","author":"RD Rubens","year":"1998","unstructured":"Rubens RD. Bone metastases \u2013 the clinical problem. Eur J Cancer. 1998;34:210\u20133.","journal-title":"Eur J Cancer"},{"key":"3272_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3111\/13696998.2013.774279","volume":"16","author":"JJ Body","year":"2013","unstructured":"Body JJ, Chevalier P, Gunther O, Hechmati G, Lamotte M. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium. J Med Econ. 2013;16:539\u201346.","journal-title":"J Med Econ"},{"key":"3272_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3111\/13696998.2013.779921","volume":"16","author":"G Hechmati","year":"2013","unstructured":"Hechmati G, Cure S, Gou\u00e9po A, Hoefeler H, Lorusso V, L\u00fcftner D, Duran I, Garzon-Rodriguez C, Ashcroft J, Wei R, Ghelani P, Bahl A. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ. 2013;16:691\u2013700.","journal-title":"J Med Econ"},{"key":"3272_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/ejhpharm-2012-000235","volume":"20","author":"M Lothgren","year":"2013","unstructured":"Lothgren M, Ribnicsek E, Schmidt L, Habacher W, Lundkvhist J, Pfeil AM, Biteeva I, Vrouchou P, Bracco A. Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland. Eur J Hosp Pharm. 2013;20:227\u201331.","journal-title":"Eur J Hosp Pharm"},{"key":"3272_CR14","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082\u201390.","journal-title":"Cancer"},{"key":"3272_CR15","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613\u201321.","journal-title":"Cancer"},{"key":"3272_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3747\/co.19.1011","volume":"19","author":"M Clemons","year":"2012","unstructured":"Clemons M, Gelmon KA, Pritchard KI, Paterson AH. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol. 2012;19:259\u201368.","journal-title":"Curr Oncol"},{"key":"3272_CR17","volume-title":"Bondronat\u00ae summary of product characteristics","author":"Roche","year":"2015","unstructured":"Roche: Bondronat\u00ae summary of product characteristics. 2015. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000101\/human_med_000678.jsp&mid=WC0b01ac058001d124\n                    \n                  . [Accessed 26 Apr 2016]."},{"key":"3272_CR18","volume-title":"ZOMETA\u00ae summary of product characteristics","author":"Novartis","year":"2016","unstructured":"Novartis: ZOMETA\u00ae summary of product characteristics. 2016. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000336\/human_med_001182.jsp&mid=WC0b01ac058001d124\n                    \n                   [Accessed 26 Apr 2016]."},{"key":"3272_CR19","volume-title":"Pamidronate disodium prescribing information","author":"Hospira","year":"2016","unstructured":"Hospira: Pamidronate disodium prescribing information. 2016. \n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/21443\n                    \n                  . [Accessed 26 Apr 2016]."},{"key":"3272_CR20","volume-title":"BONEFOS\u00ae summary of product characteristics","author":"Bayer","year":"2016","unstructured":"Bayer: BONEFOS\u00ae summary of product characteristics. 2016. \n                    https:\/\/www.medicines.org.uk\/emc\/medicine\/311\n                    \n                  . [Accessed 26 Apr 2016]."},{"key":"3272_CR21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813\u201322.","journal-title":"Lancet"},{"key":"3272_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22:679\u201387.","journal-title":"Support Care Cancer"},{"key":"3272_CR23","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082\u201392.","journal-title":"Eur J Cancer"},{"key":"3272_CR24","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132\u20139.","journal-title":"J Clin Oncol"},{"key":"3272_CR25","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1007\/s00520-013-1932-2","volume":"21","author":"R von Moos","year":"2013","unstructured":"von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013;21:3497\u2013507.","journal-title":"Support Care Cancer"},{"key":"3272_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jval.2014.10.004","volume":"18","author":"J Arellano","year":"2015","unstructured":"Arellano J, Hauber AB, Mohamed AF, Gonzalez JM, Collins H, Hechmati G, Gatta F, Qian Y. Physicians' preferences for bone metastases drug therapy in the United States. Value Health. 2015;18:78\u201383.","journal-title":"Value Health"},{"key":"3272_CR27","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.3747\/co.22.2380","volume":"22","author":"J Arellano","year":"2015","unstructured":"Arellano J, Gonz\u00e1lez JM, Qian Y, Habib M, Mohamed AF, Gatta F, Hauber AB, Posner J, Califaretti N, Chow E. Physician preferences for bone metastasis drug therapy in Canada. Curr Oncol. 2015;22:e342\u20138.","journal-title":"Curr Oncol"},{"key":"3272_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR. Conjoint Analysis Applications in Health \u2013 How are Studies being Designed and Reported?: An Update on Current Practice in the Published Literature between 2005 and 2008. Patient. 2010;3:249\u201356.","journal-title":"Patient"},{"key":"3272_CR29","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2165\/11593370-000000000-00000","volume":"29","author":"AF Mohamed","year":"2011","unstructured":"Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics. 2011;29:977\u201388.","journal-title":"Pharmacoeconomics"},{"key":"3272_CR30","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511610356","volume-title":"Applied choice analysis: a primer","author":"DA Hensher","year":"2005","unstructured":"Hensher DA, Rose JM, Greene WH. Applied choice analysis: a primer. Cambridge: Cambridge University Press; 2005."},{"key":"3272_CR31","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511753831","volume-title":"Stated choice methods: analysis and applications","author":"JJ Louviere","year":"2000","unstructured":"Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. Cambridge: Cambridge University Press; 2000."},{"key":"3272_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis applications in health \u2013 a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403\u201313.","journal-title":"Value Health"},{"key":"3272_CR33","volume-title":"XGEVA\u00ae prescribing information","author":"Amgen","year":"2016","unstructured":"Amgen: XGEVA\u00ae prescribing information. 2016. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125320Orig1s177lbl.pdf\n                    \n                  . [Accessed 22 Apr 2016]."},{"key":"3272_CR34","volume-title":"ZOMETA\u00ae prescribing information","author":"Novartis","year":"2015","unstructured":"Novartis: ZOMETA\u00ae prescribing information. 2015. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021223s034lbl.pdf\n                    \n                  . [Accessed 22 Apr 2016]."},{"key":"3272_CR35","volume-title":"XGEVA\u00ae summary of product characteristics","author":"Amgen","year":"2015","unstructured":"Amgen: XGEVA\u00ae summary of product characteristics. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002173\/WC500110381.pdf\n                    \n                  . [Accessed 26 Apr 2016]."},{"key":"3272_CR36","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1023\/A:1012506426440","volume":"12","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001;12:1433\u20138.","journal-title":"Ann Oncol"},{"key":"3272_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","volume":"246","author":"B Kristensen","year":"1999","unstructured":"Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999;246:67\u201374.","journal-title":"J Intern Med"},{"key":"3272_CR38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2307\/3172883","volume":"30","author":"J Swait","year":"1993","unstructured":"Swait J, Louviere J. The Role of the Scale Parameter in the Estimation and Use of Multinomial Logit Models. J Mark Res. 1993;30:305\u201314.","journal-title":"J Mark Res"},{"key":"3272_CR39","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511753930","volume-title":"Discrete choice methods with simulation","author":"KE Train","year":"2003","unstructured":"Train KE. Discrete choice methods with simulation. Cambridge: Cambridge University Press; 2003."},{"key":"3272_CR40","volume-title":"Applications of simulation methods in environmental and resource economics","author":"KE Train","year":"2005","unstructured":"Train KE, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, editors. Applications of simulation methods in environmental and resource economics, vol. 6. Dordrecht: Springer; 2005."},{"key":"3272_CR41","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"RE Marx","year":"2005","unstructured":"Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567\u201375.","journal-title":"J Oral Maxillofac Surg"},{"key":"3272_CR42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/TCRM.S2707","volume":"4","author":"TJ Polascik","year":"2008","unstructured":"Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag. 2008;4:261\u20138.","journal-title":"Ther Clin Risk Manag"},{"key":"3272_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carri\u00e8re P. Dansey Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341\u20137.","journal-title":"Ann Oncol"},{"key":"3272_CR44","unstructured":"Hechmati G, Arellano J, Mohamed AF, Hauber AB, Qian Y, Gatta F, Haynes I, Bahl A. Patients' preferences for attributes of bone metastases treatments in France, Germany and the United Kingdom. Poster presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), Amsterdam, Netherlands, 2013."},{"key":"3272_CR45","doi-asserted-by":"crossref","unstructured":"Henry DH, von Moos R, Body J-J, Rider A, De Courcy J, Murray G, Bhowmik D, Gatta F, Arellano J, Hechmati G, Roberts Z, Qian Y Bone targeting agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the US Poster presented at the 2015 Breast Cancer Symposium, San Francisco, CA, USA, 2015.","DOI":"10.1200\/jco.2015.33.28_suppl.93"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-018-3272-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T02:48:09Z","timestamp":1569379689000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-018-3272-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3272"],"URL":"https:\/\/doi.org\/10.1186\/s12913-018-3272-x","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"1 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the IRB of the Office of Research Protection and Ethics at RTI International (the responsible study organisation) and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Participants gave their informed consent prior to their inclusion in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"GH, JA, FG and YQ are employed by Amgen and own stock. ABH is an employee of RTI Health Solutions and has no conflict of interest. AFM was employed at RTI Health Solutions during the study and has no conflict of interest. AB has received honoraria for participating in Advisory Boards from Amgen, Sanofi, Astellas, Roche, Novartis and Bayer. RvM has received research grants from Amgen, Roche and Merck. He has participated in Advisory Boards for Amgen, Roche, Novartis, Merck, MSD, and Eli Lilly. He has received speaking honoraria from Amgen and GSK. JJB has received speaking honoraria and consulting fees from Amgen and Novartis. The authors declares that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"518"}}